Search

everythinglearnresearchcommunity

for

Search:↓

The review suggests that other immune cells besides CD8+ T cells may contribute to alopecia areata and that targeting regulatory cell defects could improve treatment.

More research is needed to understand the genetic causes of Alopecia areata to develop better treatments.

Social media can help compare the effectiveness and safety of new arthritis medications.

Chronic scalp lesions with crusts and pus that heal with strong topical steroids suggest Erosive Pustular Dermatosis, confirmed by biopsy showing specific immune cells.

Discoid Lupus Erythematosus causes scalp plaques that can lead to hair loss, and antimalarial drugs are effective treatments.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

Herbal remedies can cause adverse effects and need more safety research.

The guidelines suggest a detailed approach to diagnosing and treating lupus, with a focus on regular check-ups, personalized medicine, and a range of drug options for different cases.

The paper concludes that the 1982 criteria for diagnosing systemic lupus erythematosus need updating to improve accuracy and involve dermatologists in the process.

Steroids help hair regrowth, and minoxidil slows post-steroid hair loss, but effects are temporary.

imTA and pulse therapy are effective for alopecia areata with manageable side effects, but relapse rates need improvement.

Pregnancy can increase lupus activity, but careful planning and treatment can improve outcomes.

Acitretin is effective for certain types of psoriasis, safe for long-term use, and often combined with other treatments.

Tph cells are linked to the severity of systemic lupus erythematosus.

Belimumab reduces disease activity, steroid use, and flares in lupus patients.

Minoxidil use in children may cause heart issues.

A risk prediction model can help diagnose systemic lupus erythematosus earlier in primary care.

Chemotherapy can cause permanent, non-reversible hair loss similar to pattern baldness.

COVID-19 vaccination may trigger lupus in some people.

SLE is more common among Nigerians than previously thought, especially in women, requiring early treatment.

Fibroblast changes in systemic sclerosis may help understand disease severity and treatment.

Hair loss is common in lupus patients and can be permanent or reversible, depending on the type, with various treatments available.

No systemic treatment for alopecia areata has strong evidence of effectiveness.

Systemic glucocorticosteroids are a primary treatment for various skin conditions but require careful management due to potential side effects and relapses.

Hair loss in lupus patients indicates higher disease activity.

Early detection and stopping the drug are key to managing DRESS, and careful monitoring is important due to possible severe reactions.

Most Korean systemic lupus erythematosus patients experienced hair loss, often as non-scarring diffuse hair loss, with non-scarring patch alopecia also common.

SLE patients in eastern Saudi Arabia have a generally good prognosis despite multi-organ involvement.

The document concludes that anti-dsDNA antibodies are not unique to SLE and their use as indicators is doubtful, highlighting the need for better understanding and classification of the disease.

Hair loss in lupus is different from hair loss in alopecia areata and may indicate lupus activity.